High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations

Journal of Combinatorial Chemistry

Volumn 7, Issue 4, 2005, Pages 611-617

  Wannberg, Johan ^a   Kaiser, Nils Fredrik K ^a   Vrang, Lotta ^b   Samuelsson, Bertil ^b   Larhed, Mats ^a   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b MEDIVIR AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; DRUG DESIGN; METHODOLOGY; SYNTHESIS;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HIV PROTEASE INHIBITORS; MOLECULAR STRUCTURE;

EID: 22844442612     PISSN: 15204766     EISSN: None     Source Type: Journal    
DOI: 10.1021/cc050016r     Document Type: Article

References (22)

1. Mocroft, A.; Vella, S.; Benfield, T. L.; Chiesi, A.; Miller, V.; Gargalianos, P.; d'Arminio Monforte, A.; Yust, I.; Bruun, J. N.; Phillips, A. N.; Lundgren, J. D. Lancet 1998, 352, 1725-1730.
2. Palella, F. J., Jr.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. N. Engl. J. Med. 1998, 338, 853-860.
3. Clavel, F.; Hance, A. J. N. Engl. J. Med. 2004, 350, 1023-1035.
4. Fellay, J.; Boubaker, K.; Ledergerber, B.; Bernasconi, E.; Furrer, H.; Battegay, M.; Hirschel, B.; Vernazza, P.; Francioli, P.; Greub, G.; Flepp, M.; Telenti, A. Lancet 2001, 358, 1322-1327.
5. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2004 Report on the Global AIDS Epidemic. http://www.unaids.org (UNAIDS, Geneva, 2004).
6. Alterman, M.; Björsne, M.; Mühlman, A.; Classon, B.; Kvarnström, I.; Danielson, H.; Markgren, P. O.; Nillroth, U.; Unge, T.; Hallberg, A.; Samuelsson, B. J. Med. Chem. 1998, 41, 3782-3792.
7. Alterman, M.; Andersson, H. O.; Garg, N.; Ahlsen, G.; Lövgren, S.; Classon, B.; Danielson, U. H.; Kvarnström, I.; Vrang, L.; Unge, T.; Samuelsson, B.; Hallberg, A. J. Med. Chem. 1999, 42, 3835-3844.
8. Morimoto, T.; Kakiuchi, K. Angew. Chem., Int. Ed. 2004, 43, 5580-5588.
9. Kaiser, N.-F. K.; Hallberg, A.; Larhed, M. J. Comb. Chem. 2002, 4, 109-111.
10. Wannberg, J.; Larhed, M. J. Org. Chem. 2003, 68, 5750-5753.
11. Kappe, C. O. Angew. Chem., Int. Ed. 2004, 43, 6250-6284.
12. Larhed, M.; Moberg, C.; Hallberg, A. Acc. Chem. Res. 2002, 35, 717-727.
13. Ersmark, K.; Larhed, M.; Wannberg, J. Curr. Opin. Drug Discovery Devel. 2004, 7, 417-427.
14. Wannberg, J.; Dallinger, D.; Kappe, C. O.; Larhed, M. J. Comb. Chem. 2005, 7, In press.
15. Herrero, M. A.; Wannberg, J.; Larhed, M. Synlett 2004, 2335-2338.
16. Herrmann, W. A.; Brossmer, C.; Öfele, K.; Reisinger, C. P.; Priermeier, T.; Beller, M.; Fischer, H. Angew. Chem., Int. Ed. 1995, 34, 1844-1848.
17. Netherton, M. R.; Fu, G. C. Org. Lett. 2001, 3, 4295-4298.
18. Employing the o-iodo starting material 4, competing mono dehalogenation resulted in small amounts (<10%) of non-symmetric monoamidation products.
19. Full conversion of 10 was not achieved with 3-chloroaniline as the nucleophile, which explains the relatively low isolated yield of 61 (24%).
20. No traces of inhibitor 4 or the corresponding dehalogenated arene was detected by LC/MS or NMR of the purified compounds.
21. Danielson, H.; Lindgren, M. T.; Markgren, P. O.; Nillroth, U. Adv. Exp. Med. Biol. 1998, 436, 99-103.
22. Nillroth, U.; Vrang, L.; Markgren, P. O.; Hulten, J.; Hallberg, A.; Danielson, U. H. Antimicrob. Agents Chemother. 1997, 41, 2383-2388.